SK bioscience will lead a Gates Foundation-funded project to build an AI decision-support platform that helps vaccine developers assess whether to advance candidates into large-scale phase 3 trials. The initiative, called Research Optimization & Trial Outcome Recommender (ROTOR), targets a critical bottleneck: often, validated immune correlates of protection are limited or absent, making trial-progression decisions risky and costly.
The platform will be developed in collaboration with the global health nonprofit PATH and technology consulting firm Slalom, with funding from the Bill & Melinda Gates Foundation. ROTOR will analyze clinical, immunogenicity, and scientific datasets generated during vaccine development and generate structured insights to guide R&D and clinical strategy.
What the ROTOR platform will do
ROTOR's core task is evidence synthesis. It will ingest data from vaccine studies - including assay results that often vary across methodologies - and produce recommendations that reduce the uncertainty around phase 3 go/no-go decisions. SK bioscience said the system is designed to evolve into a scalable AI solution that can be applied to multiple vaccines and disease areas, not just the initial rotavirus use case.
The platform will be built and validated using rotavirus vaccine development experience and datasets from both SK bioscience and PATH. By integrating diverse scientific evidence, it aims to make trial-progression calls more systematic. The project sits at the intersection of AI for Science & Research and AI for Healthcare, reflecting a broader push to apply machine learning to complex bio-medical decision-making.
A global consortium with deep ties
The initiative also aims to strengthen R&D capabilities among vaccine developers in low- and middle-income countries and promote reusable components across the vaccine development ecosystem. SK bioscience has long-standing collaborations with organizations such as the World Health Organization, CEPI, the International Vaccine Institute, and the U.S. Centers for Disease Control and Prevention. It recently signed a licensing agreement with the CDC for an injectable rotavirus vaccine and a separate agreement with the Gates Medical Research Institute for a respiratory syncytial virus antibody therapy.
"This project represents a new approach to reducing uncertainty in vaccine development through AI and enabling more scientific and efficient decision-making," said Ahn Jae-yong, CEO of SK bioscience. "Through this consortium, we aim to drive innovation in vaccine R&D while contributing to improved vaccine access worldwide."
Why this matters for IT and development professionals
The ROTOR platform is a real-world example of building AI decision-support tools for a data-sparse, high-stakes domain. Developers can look at how the project integrates heterogeneous data types - clinical trials, immunogenicity assays, and scientific literature - into a single recommendation engine. The design emphasis on a scalable, reusable solution means its architecture may serve as a template for other pharmaceutical or public-health AI systems. For those working on data pipelines, model validation, or decision interfaces in regulated environments, ROTOR offers a blueprint for turning experimental data into actionable, structured outputs while staying grounded in rigorous validation with partners like PATH.
Your membership also unlocks:
Sen. Mark Warner seeks public comment on draft legislation to regulate AI agents